ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivmermectin 400)
Status:
Completed
Trial end date:
2022-05-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of repurposed medications (study
drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19.
Participants will receive either study drug or placebo. They will self-report any new or
worsening symptoms or medical events they may experience while taking study drug or placebo.
This study is intended to be all remote with no in person visits, unless the study team feels
it is in the best interest of a participant to see them in person.
Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the
activation of any new drug arms. This protocol was originally registered under NCT04885530.
Per recent guidance on reporting master protocol research programs (MPRPs), a separate record
for Arm A was created.
Phase:
Phase 3
Details
Lead Sponsor:
Susanna Naggie, MD
Collaborators:
National Center for Advancing Translational Sciences (NCATS) Vanderbilt University Medical Center